Temporary blockade of contractility during reperfusion elicits a cardioprotective effect of the p38 MAP kinase inhibitor SB-203580

被引:22
|
作者
Sumida, T [1 ]
Otani, H [1 ]
Kyoi, S [1 ]
Okada, T [1 ]
Fujiwara, H [1 ]
Nakao, Y [1 ]
Kido, M [1 ]
Imamura, H [1 ]
机构
[1] Kansai Med Univ, Dept Thorac & Cardiovasc Surg, Cardiovasc Res Ctr, Moriguchi, Osaka 5708507, Japan
关键词
necrosis; contractility;
D O I
10.1152/ajpheart.01183.2004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
p38 MAP kinase activation is known to be deleterious not only to mitochondria but also to contractile function. Therefore, p38 MAP kinase inhibition therapy represents a promising approach in preventing reperfusion injury in the heart. However, reversal of p38 MAP kinase-mediated contractile dysfunction may disrupt the fragile sarcolemma of ischemic-reperfused myocytes. We, therefore, hypothesized that the beneficial effect of p38 MAP kinase inhibition during reperfusion can be enhanced when contractility is simultaneously blocked. Isolated and perfused rat hearts were paced at 330 rpm and subjected to 20 min of ischemia followed by reperfusion. p38 MAP kinase was activated after ischemia and early during reperfusion (<30 min). Treatment with the p38 MAP kinase inhibitor SB-203580 (10 mu M) for 30 min during reperfusion, but not the c-Jun NH2-terminal kinase inhibitor SP-600125 (10 mu M), improved contractility but increased creatine kinase release and infarct size. Cotreatment with SB-203580 and the contractile blocker 2,3-butanedione monoxime (BDM, 20 mM) or the ultra-short-acting beta-blocker esmorol (0.15 mM) for the first 30 min during reperfusion significantly reduced creatine kinase release and infarct size. In vitro mitochondrial ATP generation and myocardial ATP content were significantly increased in the heart cotreated with SB-203580 and BDM during reperfusion. Dystrophin was translocated from the sarcolemma during ischemia and reperfusion. SB-203580 increased accumulation of Evans blue dye in myocytes depleted of sarcolemmal dystrophin during reperfusion, whereas cotreatment with BDM facilitated restoration of sarcolemmal dystrophin and mitigated sarcolemmal damage after withdrawal of BDM. These results suggest that treatment with SB-203580 during reperfusion aggravates myocyte necrosis but concomitant blockade of contractile force unmasks cardioprotective effects of SB-203580.
引用
收藏
页码:H2726 / H2734
页数:9
相关论文
共 50 条
  • [1] Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase
    Ward, KW
    Proksch, JW
    Azzarano, LM
    Mumaw, JA
    Roethke, TJ
    Stelman, GJ
    Walsh, MJ
    Zeigler, KS
    McSurdy-Freed, JE
    Kehler, JR
    Chokshi, J
    Levy, MA
    Smith, BR
    XENOBIOTICA, 2001, 31 (11) : 783 - 797
  • [2] Effect of the p38 kinase inhibitor, SB203580, in a model of airway inflammation
    Birrell, M
    Haddad, EB
    McCluskie, K
    Hele, D
    Phipps, S
    Webber, SE
    Foster, M
    Belvisi, MG
    BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 : U46 - U46
  • [3] Effect of the p38 kinase inhibitor, SB 203580, on sephadex induced airway inflammation in the rat
    Birrell, M
    Hele, D
    McCluskie, K
    Webber, S
    Foster, M
    Belvisi, MG
    EUROPEAN RESPIRATORY JOURNAL, 2000, 16 (05) : 947 - 950
  • [4] Reversal of Adrenergic Desensitization in Prenatally Stressed Rats by P38 Map Kinase Inhibitor, SB203580
    Chen, Fangping
    Kan, Hong
    Xie, Sherry
    Beto, Robert J.
    Warden, Bradford E.
    Jain, Abnash C.
    Finkel, Mitchell S.
    FASEB JOURNAL, 2008, 22
  • [5] Effect of the p38 kinase inhibitor, SB203580, on sephadex-induced airway inflammation in the rat
    Birrell, MA
    Battram, CH
    McCluskie, K
    Pecoraro, M
    Webber, SE
    Foster, ML
    Belvisi, MG
    BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 : U119 - U119
  • [6] Effect of attenuation of p38α or p38β MAP kinase activity on myocardial contractility and ischemic injury
    Cross, HR
    Murphy, E
    Zheng, MZ
    Wang, YB
    Steenbergen, C
    CIRCULATION, 2001, 104 (17) : 101 - 101
  • [7] SB-203580 IS A SPECIFIC INHIBITOR OF A MAP KINASE HOMOLOG WHICH IS STIMULATED BY CELLULAR STRESSES AND INTERLEUKIN-1
    CUENDA, A
    ROUSE, J
    DOZA, YN
    MEIER, R
    COHEN, P
    GALLAGHER, TF
    YOUNG, PR
    LEE, JC
    FEBS LETTERS, 1995, 364 (02) : 229 - 233
  • [8] Effect of the p38 kinase inhibitor, SE 203580, on allergic airway inflammation in the rat
    Escott, KJ
    Belvisi, MG
    Birrell, MA
    Webber, SE
    Foster, ML
    Sargent, CA
    BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (02) : 173 - 176
  • [9] Expression of synphilin-1 in vascular endothelial cells and its enhancement by SB203580, an inhibitor of p38 MAP kinase
    Tamo, W
    Imaizumi, T
    Yoshida, H
    Mori, F
    Fukuda, I
    Wakabayashi, K
    Satoh, K
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 61 - 61
  • [10] SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes
    Henklova, Pavla
    Vrzal, Radim
    Papouskova, Barbora
    Bednar, Petr
    Jancova, Petra
    Anzenbacherova, Eva
    Ulrichova, Jitka
    Maurel, Patrick
    Pavek, Petr
    Dvorak, Zdenek
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 593 (1-3) : 16 - 23